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ISSObjective: To determine the safety and effectiveness of BufferGel and 0.5% PRO2000
microbicide gels for the prevention of male-to-female HIV transmission.
Design: Phase II/IIb, randomized, placebo-controlled trial with three double-blinded
gel arms and an open-label no gel arm.
Methods: Study participants from Malawi, South Africa, Zambia, Zimbabwe, and the
USA were instructed to apply study gel up to 1 h before each sex act and safety, sexual
behavior, pregnancy, gel adherence, acceptability, and HIV serostatus were assessed
during follow-up.
Results: The 3101 enrolled women were followed for an average of 20.4 months with
93.6% retention and 81.1% self-reported gel adherence. Adverse event rates were
similar in all study arms. HIV incidence rates in the 0.5% PRO2000 gel, BufferGel,
placebo gel, and no gel arms were 2.70, 4.14, 3.91, and 4.02 per 100 women-years,
respectively. HIV incidence in the 0.5% PRO2000 gel arm was lower than the placebo
gel arm (hazard ratio¼0.7, P¼0.10) and the no gel arm (hazard ratio¼0.67, P¼0.06).
HIV incidence rates were similar in the BufferGel and both placebo gel (hazard
ratio¼1.10, P¼0.63) and no gel control arms (hazard ratio¼1.05, P¼0.78).
HIV incidence was similar in the placebo gel and no gel arms (hazard ratio¼0.97,
P¼0.89).
Conclusion: The 0.5% PRO2000 gel demonstrated a modest 30% reduction in HIV
acquisition in women. However, these results were not statistically significant and
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Globally, most new HIV infections are acquired through
heterosexual contact [1]. Although correct and consistent
condom use has been shown to prevent HIV transmission
[2], this method may not be applicable for women who
are trying to become pregnant or who are unable to
negotiate condom use with their male partners [3–5].
Microbicides are products that can be applied to the
vagina or rectum with the intention of reducing the
acquisition of sexually transmitted infections including
HIV. Microbicides could fill an important HIV preven-
tion gap, especially for those women who are unable to
successfully negotiate mutual monogamy or condom use.
Before effectiveness trials on PRO2000 gel (Endo
Pharmaceuticals Solutions Inc. (formerly Indevus Phar-
maceuticals Inc.), Lexington, Massachusetts, USA) and
BufferGel (ReProtect Inc., Baltimore, Maryland, USA)
were initiated, six candidate microbicides had been
assessed for their effectiveness in preventing HIV
infection. These were nonoxynol-9 (N9) sponge [6],
N9 film [7], N9 gel [8–10], Savvy [11], cellulose sulfate
[12], and Carraguard [13]. Clinical trials of N9 film,
Carraguard, and one study of cellulose sulfate showed no
impact on HIV acquisition. The Savvy trial was halted
early owing to futility. Two N-9 studies [6,10] and a
second cellulose sulfate trial [12] showed some increase,
although not always statistically significant, in HIVamong
women randomized to the active arms.
BufferGel and PRO2000 gel are two novel vaginal
products that showed good acceptability and short-term
safety in phase I and phase II trials conducted in the USA
[14,15], Europe [16], India [17], and several countries in
Africa [14,16,18,19]. BufferGel was designed to protect
against HIV infection by maintaining the normally acidic
vaginal pH in the presence of ejaculate [20]. PRO2000
gel contains an anionic polymer and was designed to
protect against HIV infection by inhibiting viral attach-
ment and entry into susceptible cells [14,15].
Soon after the initiation of the HIV Prevention Trials
Network (HPTN) 035 trial, the Microbicide Develop-
ment Programme (MDP) initiated a large phase III trial of
0.5 and 2% concentrations of PRO2000 gel, which has,
subsequent to the presentation of the HPTN 035 trial
results, shown that both concentrations of PRO2000 have
little or no protective effect on HIV [21].incott Williams & Wilkins. UnauthoThe objective of HPTN 035 trial was to determine the
safety and effectiveness of BufferGel and 0.5% PRO2000
gel in preventing HIV infection in women. Here we
describe the trial design, key characteristics of the trial
participants, and the primary outcome of the effect of
BufferGel, PRO2000 gel, and hydroxyethylcellulose
(HEC) placebo gel on HIV acquisition.Methods
Study design and population
HPTN 035 was a phase II/IIb, four-arm, multisite,
randomized controlled trial conducted between February
2005 and January 2009, at multiple sites in Blantyre and
Lilongwe, Malawi; Durban and Hlabisa, South Africa;
Harare and Chitungwiza, Zimbabwe; Lusaka, Zambia;
and Philadelphia, USA.
HIV-negative nonpregnant women, at least 18 years of
age, who were sexually active, defined as having had
vaginal intercourse at least once in the past 3 months were
eligible for the study. The exclusion criteria included a
history of adverse reactions to latex, use of nontherapeutic
injection drugs in the past 12 months, and a history of
vaginal intercourse more than an average of two times per
day in the past 2 weeks.
Study procedures
All participants demonstrated adequate understanding of
the trial and provided written informed consent. Women
were randomly assigned in equal proportions to one of the
four study arms: BufferGel, 0.5% PRO2000 gel, and two
comparator arms comprising HEC placebo gel, or no gel.
All three study gels were similar in appearance and were
packaged in identical vaginal applicators. Randomization
was stratified by site in blocks of size 12 or 24, distributed
randomly. Within each block of size 12 (24), three (six)
assignments to each of the four treatment arms were
allocated in random order. For the three gel arms, each of
the three assignments within a block was associated with a
unique three-digit code that was labeled on the product
packaging. In blocks of size 24, each unique three-digit
code was used twice. Each random sequence was
determined through generation of uniform random
variates in a computer program (SAS; Statistical Analysis
System Institute Inc., Cary, North Carolina, USA) and
envelope materials were created and sealed at therized reproduction of this article is prohibited.
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three gel groups were double-blinded, whereas the no gel
group was open label. Upon enrollment of a participant at
each site, clinic staff opened an envelope revealing
assignment to any gel group or to no gel. For those
assigned to any gel group, a corresponding envelope was
opened only by the pharmacist to reveal the three-digit
code of the gel product to be prescribed. All persons
associated with the study were masked to the product
identity of the three-digit codes throughout the course of
the trial, except for the product manufacturers and one
independent (not associated with the trial) statistician at
the SDMC. Women assigned to a gel arm were requested
to insert one applicator of gel intravaginally up to 1 h
before each episode of vaginal intercourse.
The first 799 women enrolled comprised a ‘lead in’ phase II
safety study that included intensive safety assessments such
as hematological, coagulation, hepatic, and renal function
tests and monthly pelvic examinations for 3 months. In
addition, 299 of these women underwent monthly
colposcopy by trained colposcopists at the Philadelphia,
Harare, Chitungwiza, Durban, and Lilongwe sites.
All women were provided comprehensive HIV preven-
tion services, including HIV pretest, risk reduction, and
posttest counseling, condoms and sexually transmitted
infection testing and treatment as per local standards.
The Data and Safety Monitoring Board (DSMB)
reviewed the phase II safety data and recommended
proceeding with the phase IIb effectiveness trial. All
observations prior to the DSMB review were included as
part of the phase IIb analysis.
In phase IIb, study participants were followed monthly for
12–30 months based on date of enrollment. At each
monthly visit they had a urine pregnancy test before study
product was dispensed. Women testing positive for
pregnancy were required to temporarily discontinue gel
use while continuing follow-up in the trial. Product use
was re-initiated when the urine pregnancy test was nega-
tive. Self-reported data on gel and condom use during the
last coital act and during all coital acts in the last 7 days were
collected at quarterly visits. We calculated gel adherence as
the proportion of women who reported applying gel
during their last sex act from the data collected at the
quarterly study visits. Condom use was calculated as the
proportion of women who reported using a condom dur-
ing their last sex act from the data collected at the quarterly
study visits. Study participants also had quarterly HIV tests
and medical and speculum-aided pelvic examinations.
Local mucosal toxicity was assessed by the incidence of
deep epithelial disruption, observed on pelvic examin-
ation (speculum and/or colposcopic) as lesions penetrat-
ing into and exposing the subepithelial tissue and possibly
blood vessels [22]. Additional safety outcomes includedopyright © Lippincott Williams & Wilkins. Unauthadverse genital signs and symptoms, as well as hemato-
logical, hepatic, and renal abnormalities of grade 3 or
higher severity based on the Division of AIDS Table for
Grading Adult and Paediatric Adverse Events, 2004.
Laboratory tests
HIV infection status was determined using a standardized
algorithm, which was validated at each site. At the US
site, the OraQuick ADVANCE HIV-1/2 antibody test
(Orasure Technologies, Bethlehem, Pennsylvania, USA)
was used. In the African sites, two rapid tests were used;
the Determine HIV 1/2 (Abbott Diagnostic Division,
Hoofddorp, The Netherlands) test was used with either
the OraQuick or Uni-Gold Recombigen HIV test
(Trinity Biotech, Wicklow, Ireland). The Zambia site
used only the OraQuick assay during follow–up.
Western blot (Genetics systems HIV-1 Western Blot kit;
BioRad Laboratories, Hercules, California, USA) was
performed on samples with any positive HIV result. If
the western blot result was indeterminate or positive,
a second blood sample was collected (approximately
2 weeks later) for further western blot testing. If the
second western blot result was positive, HIV infection was
considered confirmed. For women who tested HIV-
positive in their first follow-up visit, plasma stored at
study entry was tested by a RNA-PCR to identify
women who may have been in the window period of
acute HIV infection at enrolment. Women found to be in
the window period at enrolment were deemed ineligible
and were excluded from the primary analysis.
Statistical analyses
The phase II portion of the study was designed to enroll
800 women and follow each of them for 3 months,
resulting in approximately 50 person-years of follow-up
per randomization arm. Assuming a two-sided test with a
false-positive rate of 0.05, this provides 80% power to
detect a three-fold difference between the active and the
placebo arms in safety measurements with baseline rates of
at least 15 per 100 woman-years. The phase IIb portion of
the study was designed to enroll 3100 women followed
through the study end date or for a maximum of
30 months, whichever occurred first (with minimum
follow-up of 12 months). The study end date was set as
the date upon which a total of 192 incident HIV
infections were observed. The number of incident
infections was based on a four-point decision guideline
for this screening trial: if the estimated effectiveness of a
candidate microbicide is less than 15.3%, exclude the
candidate microbicide from further testing for HIV
prevention; if the estimated effectiveness is greater than
15.3%, but less than or equal to 33%, consider the product
plausibly effective and meriting further evaluation; if the
estimated effectiveness is between 33 and 43.6%, consider
the product effective with strength of evidence equal to
that of at least a single phase III study; and if the estimated
effectiveness is greater than 43.6%, consider the productorized reproduction of this article is prohibited.
Co
960 AIDS 2011, Vol 25 No 7effective with the strength of evidence of at least 1.5 phase
III studies. Additional details regarding the statistical
rationale for the study design and sample size have been
published elsewhere [23].
Owing tovery low loss to follow-up, complete case analysis
was used for all analyses. The primary analysis was intent-
to-treat. Discrete-time Cox proportional hazards models
stratified by site were used to assess time to detection of
HIV. Cumulative probabilities of infection were estimated
using the Kaplan–Meier method. Incidence rates of
epithelial disruption were compared using Andersen–Gill
proportional hazards models stratified by site. Analyses
stratified by adherence and condom use were post-hoc
analyses. All reported P-values were two-sided.
Ethics
The trial (NCT00074425) was approved by 11 institu-
tional review boards that oversee research conducted at
the eight study sites, as well as regulatory authorities in the
USA, South Africa, and Zimbabwe.Results
Between 2005 and 2007, 5888 women were screened
and 3101 were enrolled (Fig. 1). Twelve women were
subsequently excluded because they were HIV-infected atpyright © Lippincott Williams & Wilkins. Unautho
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Fig. 1. Screening, randomization, and follow-up of the study par
trial.the time of enrolment and two women were identified as
having enrolled twice. A further 37 women did not attend
any follow-up visits. The remaining 3050 women were
included in the primary analysis. The baseline charac-
teristics and sexual behaviors were similar across the four
study arms (Table 1).
Mean follow up was 20.4 months and overall study
retention, defined as the proportion of those enrolled
(except the window period infections) who had a
study exit visit with an HIV test, was 93.6%. Of the
5258 person-years of follow-up accumulated on 3050
women (Fig. 1), 240 person-years (6.1%) in 620 women
comprised follow-up during which study product was
temporarily withheld, mostly due to pregnancy, in
accordance with the study protocol. Women reported
using gel in 81.1% of last sex acts. Gel adherence was
similar in the three gel arms. Self-reported condom
use during the last sex act was similar in the three gel
arms, but higher in the no gel arm (71.7 vs. 80.7%,
P¼<0.0001). Overall, women reported gel use in
conjunction with condoms during study follow-up in
61.3% of sex acts. Gel was used in 69.1% of last acts in
which a condom was not used.
The HIV incidence rate per 100 person-years was 4.1
(54 of 1304) in the BufferGel arm, 2.7 (36 of 1332) in the
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Table 1. Baseline demographic characteristics, sexual history, and contraceptive use by enrolled study participants in the HIV Prevention Trials










Mean age (years) 26.2 26.3 26.5 26.3
Age range (years) 18–55 18–52 18–53 17–56
Percentage that were between 17 and 24 years (%) 45 46 44 46
Married (%) 62 62 63 63
Own income (%) 43 39 42 40
At least some secondary school (%) 63 64 62 63
Sexual behavior
Mean number of vaginal sex acts in past 7 days 2.8 2.9 2.8 3.0
Condom use in the last sex act (%) 67 68 69 67
Ever had anal sex (%) 4 4 5 5
Anal sex in past 7 days (%) 1 <1 1 1
For last sex act, douched before sex (%) 24 27 24 26
For last sex act, douched after sex (%) 30 29 26 27
Contraception
Hormonal contraception (oral) (%) 20 20 19 20
Hormonal contraception (injectable) (%) 49 46 49 47gel arm, and 4.0 (53 of 1318) in the no gel arm (Table 2).
The hazard ratio of HIV incidence rates in 0.5%
PRO2000 gel arm compared with the placebo gel arm
was 0.70 (P¼ 0.10) and with the no gel arm was 0.67
(P¼ 0.06). Figure 2 shows how the Kaplan–Meier
survival curves from HIV infection in the 0.5% PRO2000
gel arm differs from the remaining three study arms. The
HIV incidence rate in the 0.5% PRO2000 gel arm was
lower, though not statistically significant, than the rate in
the placebo gel arm at seven of the eight sites (Table 3). In
the per-protocol analysis that excludes follow-up beyond
2 months after initiating product hold, the hazard ratio of
HIV incidence rates in the 0.5% PRO2000 gel arm was
0.71 (P¼ 0.13) compared with the placebo gel arm and
0.64 (P¼ 0.04) compared with the no gel arm. There was
no difference in HIV incidence between the BufferGel
and both control arms (Table 3).
The hazard ratio of the HIV incidence rates in the placebo
gel arm compared with the no gel arm was 0.97
(P¼ 0.89), reflecting the similarities in the HIV incidence
rates in the placebo gel arm [3.9 per 100 person-years,
95% confidence interval (CI) 2.9–5.1] and in the no gel
arm (4.0 per 100 person-years, 95% CI 3.0–5.3). There
was little change in this hazard ratio after adjusting for
baseline sexual behavior and participant characteristics.opyright © Lippincott Williams & Wilkins. Unauth
Table 2. Retention, gel and condom use, and HIV incidence rates for each t
0.5% PRO2000 g
N 769
Retention rate (%) 93.6
Percentage condom use in last sex act 71.8
Percentage gel use in last sex acta 80.5
Percentage gel use in sex acts with no condomsa 68.2
Person-years of follow-up 1332.0
Number of HIV seroconversions 36
HIV incidence rates 2.7
aCalculated for the three gel arms only.In order to assess whether self-reported PRO2000 gel use
was associated with a lower rate of HIV, a subgroup
analysis stratified low and high gel users at the median;
women with 85% or more gel use in their quarterly
reported last sex acts were categorized as high gel users,
whereas those with less than 85% gel use were categorized
as low gel users. The HIV incidence rate among low gel
users was 3.0 per 100 person-years (18 of 592) in the 0.5%
PRO2000 gel group and 3.3 per 100 person-years (19 of
568) in the placebo gel group (hazard ratio¼ 1.04, 95%
CI 0.55–2.00). However, the HIV incidence rate among
high gel users was 2.4 per 100 person-years (18 of 740) in
the 0.5% PRO2000 gel group and 4.3 per 100 person-
years (32 of 738) in the placebo gel group (hazard
ratio¼ 0.55, 95% CI 0.31–0.98). In the low condom use
(less than 85% condom use in quarterly reported last sex
acts) subgroup of the high gel users, the HIV incidence
rate was 1.0 per 100 person-years (three of 299) in the
0.5% PRO2000 gel group and 4.6 per 100 person-years
(15 of 324) in the placebo gel group (hazard ratio¼ 0.21,
95% CI 0.06–0.73).
After adjusting for multiple comparisons, there were no
statistically significant differences in systemic and local
adverse events among the four study arms in the intent-
to-treat and per-protocol analyses. Overall, the incidenceorized reproduction of this article is prohibited.
reatment arm in the HIV Prevention Trials Network (HPTN) 035 trial.
el BufferGel Placebo gel No gel Overall
775 771 772 3087
93.5 93.1 94.0 93.6
71.8 71.3 80.7 71.7
81.5 81.3 – 81.1
69.3 69.9 – 69.1
1303.8 1305.0 1317.5 5258.3
54 51 53 194
4.1 3.9 4.0 3.7
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Fig. 2. Kaplan–Meier graph of HIV-1-free survival in each of the four study arms in the HIV Prevention Trials Network (HPTN)
035 trial.rate of deep epithelial disruption was 1.55 per 100 person-
years, with rates being similar across the four study arms
(Table 4). The higher incidence of blood in the vagina
with no identified source (Table 4) in the 0.5% PRO2000
gel arm was statistically significant compared with the
placebo gel arm (3.5 vs. 1.8, P< 0.01), but not compared
with the no gel arm (3.5 vs. 2.3, P¼NS). After adjusting
for multiple comparisons, these differences were no
longer statistically significant. A total of 613 pregnancies
occurred during follow-up in the study yielding an
overall pregnancy rate of 11.3 per 100 person-years.
Pregnancy rates were similar across the four study arms.
The lowest pregnancy rate was 9.2 per 100 person-years
(95% CI 7.0–11.4) at the combined Harare and
Chitungwiza sites in Zimbabwe and the highest was
16.5 per 100 person-years (95% CI 13.4–19.5) at the
Blantyre site (Table 4).
The overall incidence rates of infection with Neisseria
gonorrheae, Chlamydia trachomatis, Trichomonas vaginalis, and
Treponema pallidum, as well as bacterial vaginosis were 1.6,
3.9, 15.3, 0.9, and 160.5 per 100 person-years, respect-
ively. These infection rates were similar in the four
study arms.Discussion
The HPTN 035 trial showed that 0.5% PRO2000 gel was
well tolerated and, compared with the placebo gel,
reduced the incidence of HIV infection by a modest 30%,
although this finding was not statistically significant
(P¼ 0.10). The consistent presence of the 0.5%
PRO2000 effect on HIV infection against each of the
two comparator arms and in almost all study sites, thepyright © Lippincott Williams & Wilkins. Unauthogreater protection observed in self-reported high
PRO2000 gel users compared with low gel users, and
the biological plausibility from animal challenge studies
[24,25] suggested a potentially promising signal on
PRO2000. However, these data alone were insufficient
to conclude that 0.5% PRO2000 gel protected against
HIV infection. Subsequently, our trial’s initial encoura-
ging signal was superseded by the finding of no protection
against HIV infection in the phase III MDP301 trial [21].
The HEC placebo gel [26] was found to be well tolerated
and had no demonstrable effect on HIV infection when
compared with the no gel arm, even after adjusting for
baseline characteristics including condom use. This
addressed a key concern in microbicide research and
makes HEC a suitable ‘universal’ placebo for future
microbicide gel trials [26].
The results of microbicide effectiveness trials are impacted
by several inherent design and implementation challenges
[27], including lengthy periods off-product (mainly due
to pregnancy), adherence, other sexually transmitted
infections, unprotected and unreported anal sex, use of
intravaginal substances that may interfere with the study
gel, and difficulties in applying study gel as prescribed.
The 6.1% of follow-up time that was off-product, mainly
due to the 11.3% pregnancy rate, had little, if any, effect in
the placebo gel comparisons. However, it had a small but
important impact in the comparisons with the no gel
arm in which the effect of PRO2000 changed from
33% (P¼ 0.06) in the intent-to-treat analysis to 36%
(P¼ 0.04) in the per-protocol analysis, highlighting the
potential impact of even relatively modest pregnancy rates
on microbicide trial outcomes. Adherence is a major
challenge in microbicide trials [28]. In the recentrized reproduction of this article is prohibited.
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Participants with adverse events
Deaths 2 (0.3%) 2 (0.3%) 1 (0.1%) 2 (0.3%) 7 (0.2%)
Hospitalizations 37 (5.6%) 30 (3.9%) 30 (3.9%) 33 (4.3%) 130 (4.2%)
Reproductive system events 412 (53%) 393 (51%) 387 (50%) 375 (49%) 1567 (51%)
Vaginal discharge 229 (30%) 221 (29%) 202 (26%) 223 (29%) 875 (28%)
Vulvovaginal pruritus 115 (15%) 97 (13%) 105 (14%) 90 (12%) 407 (13%)
Metrorrhagia 53 (7%) 55 (7%)M 36 (5%) 51 (7%) 195 (6%)
Cervix hemorrhage uterine 39 (5%) 37 (5%) 36 (5%) 40 (5%) 152 (5%)
Menorrhagia 34 (4%) 31 (4%) 29 (4%) 35 (5%) 129 (4%)
Adverse event categories
Genital infection events 563 (73%) 577 (75%) 557 (72%) 561 (73%) 2258 (73%)
Genital irritation events 317 (41%) 308 (40%) 302 (39%) 281 (36%) 1208 (39%)
Genital bleeding abnormality events 140 (18%) 135 (18%) 116 (15%) 143 (19%) 534 (17%)
Urinary tract events 126 (16%) 132 (17%) 109 (14%) 106 (14%) 473 (15%)
Genital pain events 79 (10%) 78 (10%) 73 (9%) 65 (8%) 295 (10%)
Genital lesion events 78 (10%)MM 63 (8%) 53 (7%) 70 (9%) 264 (9%)
Intermenstrual bleeding events 56 (7%) 63 (8%)MMM 39 (5%) 54 (7%) 212 (7%)
Pregnancy-related events 41 (5%) 39 (5%) 30 (4%) 40 (5%) 150 (5%)
Coagulation abnormalities 2 (0.3%) 4 (0.5%) 2 (0.3%) 2 (0.3%) 10 (0.3%)
Systemic liver, renal and coagulation
abnormalities during phase II
(or participants in phase II)
1/195 (0.5%) 2/201 (1.0%) 1/201 (0.5%) 1/196 (0.5%) 5/793 (0.6%)
Pelvic examination findings (events per 100 person-years)
Deep epithelial disruption 1.1 1.7 1.5 1.9 1.5
Abnormal vaginal discharge 77.4 78.2 73.7 73.0 75.6
Any blood-related finding 17.4 16.1 15.3 14.9 15.9
Blood from cervical os 10.7 9.8 10.5 8.5 9.8
Erythema 6.3y 7.9 7.4 10.9 8.2
Petechia 5.0 3.9 4.6 5.2 4.7
Blood-tinged discharge 4.0 2.4 2.6 3.8 3.2
Blood in vagina, no identified source 2.5 3.5z 1.8 2.3 2.5
Ulceration 2.6 1.9 1.9 3.5 2.5
Pregnancy rate (per 100 person-years) 11.2 12.0 9.9 12.2 11.3




yP¼0.02 vs. no gel.
zP<0.01 vs. placebo.Carraguard trial, an applicator dye test revealed a much
lower estimate of use compared with self-reported
adherence (42.1 vs. 96.1%) [13]. Our trial did not have
such an objective measure of adherence because the dye
test performed poorly on the applicator used in this trial
[29]. To increase their chances of success, future
microbicide trials will need to enroll a higher proportion
of women who will maintain high adherence for both
study gel and reliable contraception during the trial.
Although interpretation of microbicide trial results can be
complicated by the indirect effect of other sexually
transmitted infections on HIV infection, this did not
apply to this trial, as the three study gels did not alter the
risk of other sexually transmitted infections. Self-reported
unprotected anal sex, intravaginal substance use, and
concerns about the 1-h presex insertion requirement
were low and, therefore, unlikely to have had an impact
on the trial result. However, these may have been under-
reported, making it difficult to estimate their full potential
impact on the study outcome.pyright © Lippincott Williams & Wilkins. UnauthoBufferGel was found to be well tolerated, but did not alter
the risk of HIV infection. This could be due to the
differential effect of acidity and BufferGel on cell-free [30]
compared with cell-associated viruses [31]. Moreover, the
duration of action of BufferGel is brief [32]. It was posited
that BufferGel would reduce HIV susceptibility by reduc-
ing the prevalence of bacterial vaginosis, as observed in a
phase I trial [19]; however, no effect on bacterial vaginosis
was observed in this trial, possibly due to lower gel use here
compared with twice-daily use in the phase I trial.
The pregnancy rates in all arms were similar. Although
HPTN 035 was not specifically designed to assess
contraceptive efficacy due to the high background rates
of effective contraception use in the study population,
0.5% PRO2000 gel and BufferGel did not demonstrate a
contraceptive effect in this study.
Viewed jointly, the HPTN 035 and MDP 301 trials
suggest that 0.5% PRO2000 gel may have little or no
effect on reducing a woman’s risk of HIV infection. Hoperized reproduction of this article is prohibited.
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agents, like tenofovir gel [33], as the next class of candidate
microbicides and on new formulations to improve
adherence, like vaginal rings. Most recently, results from
the Centre for the AIDS Programme of Research in South
Africa (CAPRISA) 004 trial showed that tenofovir gel had
a protective effect of 39% against HIV [33]. The protective
efficacyof tenofovir gel has demonstrated that microbicides
can prevent HIV infection and could potentially alter the
course of the HIVepidemic [34]. Although efforts to bring
tenofovir gel into widespread public health use are
underway, there are limitations to using prescription-only
medications, including their potential for drug resistance,
and potential adverse effects on concomitant viral
infections such as hepatitis B. For these reasons, the
microbicide field should not abandon the search for a well
tolerated, single use with sex, over-the-counter micro-
bicide, as had been hoped for when we undertook this
study of PRO2000 gel and BufferGel.Acknowledgements
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